BACKGROUND: Neovascular age-related @entity1020 is characterized by @entity1940 that has a complex pathogenesis. Combining agents that have different mechanisms of action (i.e., @entity4936 photodynamic therapy, antivascular endothelial growth factor, and/or anti-inflammatory therapies) could maximize clinical benefits through potential complementary effects. This review discusses findings from studies investigating this hypothesis. METHODS: Articles were retrieved from PubMed using relevant search terms. Abstracts from recent scientific meetings and details of ongoing trials from clinicaltrials.gov were also included. RESULTS: Following its approval, verteporfin was important in the management of @entity1940 due to age-related @entity1020 for several years. Improved visual outcomes have now been reported with antiangiogenic agents (e.g., intravitreal ranibizumab), especially when frequently administered. Results from investigator-sponsored trials, retrospective case studies and Registries, which have provided insights into the latest findings from clinical practice in the "real-world" setting, as well as randomized controlled trials, suggest that a combination approach is generally well tolerated and may maintain improvements in visual and anatomic outcomes with fewer retreatments. CONCLUSION: A rationale exists for investigating combination approaches to target different processes in @entity1940 pathogenesis, which may optimize treatment benefits in neovascular age-related @entity1020 . Encouraging data suggest that combination strategies are not associated with major adverse events.

@entity4936 combination regimens in the treatment of neovascular age-related XXXX .

@entity1020 :: ('MESH:D008268', 'Disease') :: ['macular degeneration'] @entity4936 :: ('MESH:C098350', 'Chemical') :: ['verteporfin'] @entity1940 :: ('MESH:D020256', 'Disease') :: ['choroidal neovascularization']
@entity1020 :: (MESH:D008268,Disease) :: ['macular degeneration']
